Share Your Insights

Speaker Proposals Now Being Accepted


Register with Confidence



Your safety and comfort are our priority. To provide maximum flexibility to match your needs, CHI provides this event as both an in-person and virtual experience. We feel the combination of these two experiences will bring about a truly unique event. This new conference norm will fuse the best of our traditional onsite events with the expanded benefits of a virtual conference. Bringing together the life sciences community is what CHI does, and we look forward to bringing our community together with this new offering.

Flexible Registration – Seamlessly switch between In-Person and/or Virtual

Select an in-person or virtual option, and you have the flexibility to switch your preferred event experience at any time leading up to the conference. Simply contact us, and we will either charge you the difference for upgrading to in-person or credit back the price for transferring to virtual. Our flexible registration is designed to take the uncertainties out of these uncertain times.





Premier & Corporate Sponsors







The Discovery on Target Community Reconnects in 2021!

Discovery on Target (DOT) is the industry’s preeminent event on novel drug targets and technologies for drug discovery professionals. DOT highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents, ranging from biologics to small molecules.

We aim to meet your research needs. Delegates can visit numerous concurrent sessions in-person and online and – with on-demand access to presentations – benefit even from those you can’t attend live. You can customize your experience further through focused short courses, interactive discussions, and networking options that help you engage with experts and solutions providers onsite, or from the comfort of home!



William G. Kaelin, Jr., MD

2020 Plenary Keynote: Tackling Undruggable Oncoproteins: Lessons from the VHL Tumor Suppressor Protein

William G. Kaelin, Jr., MD

2019 Nobel Laureate; Sidney Farber Professor of Medicine, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School; Investigator, Howard Hughes Medical Institute (Co-Founder, Cedilla Therapeutics and Co-Founder, Tango Therapeutics)

Dr. Kaelin received the 2019 Nobel Prize in Physiology or Medicine. Dr. Kaelin is a member of the American Society of Clinical Investigation, the American College of Physicians, the National Academy of Sciences and the National Academy of Medicine.


READ MORE


PANEL DISCUSSION: De-Risking Early Drug Discovery

Moderator: Nadeem Sarwar, PhD
Founder & President, Eisai Center for Genetics Guided Dementia Discovery, Eisai, Inc.

Anthony A. Philippakis, PhD
Chief Data Officer, Data Sciences & Data Engineering, Broad Institute, Venture Partner, GV

Stephen A. Hitchcock, PhD
Head, Research, Takeda Pharmaceuticals, Inc.





Missed Discovery on Target 2020? On-Demand Access is Available!


Missed 2020’s virtual event? Access content across all of our programs On-Demand. At your convenience, view archived presentations for year-long learning, from anywhere, at any time.